Federated Hermes
KYTX icon

Federated Hermes’s Kyverna Therapeutics KYTX Stock Holding History

Federated Hermes’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Buy
30,705
+10,000
+48% +$88.8K ﹤0.01% 1469
2026
Q1 		$179K Hold
20,705
– – ﹤0.01% 1513
2025
Q4 		$195K Buy
20,705
+5,547
+37% +$41.2K ﹤0.01% 1499
2025
Q3 		$90.9K Sell
15,158
-28,842
-66% -$115K ﹤0.01% 1591
2025
Q2 		$135K Buy
44,000
+8,000
+22% +$19.8K ﹤0.01% 1550
2025
Q1 		$69.5K Buy
36,000
+4,000
+13% +$11.8K ﹤0.01% 1607
2024
Q4 		$120K Hold
32,000
– – ﹤0.01% 1554
2024
Q3 		$156K Buy
32,000
+16,000
+100% +$123K ﹤0.01% 1518
2024
Q2 		$120K Buy
+16,000
New +$244K ﹤0.01% 1547

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Federated Hermes's KYTX Position: Q2 2026 in Review

Federated Hermes increased its Kyverna Therapeutics (KYTX) stake by 48% in Q2 2026, buying an estimated $88.8K and bringing the position to 30,705 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

Federated Hermes first reported a position in KYTX in Q2 2024 and has held it in 9 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Federated Hermes held 30,705 shares of Kyverna Therapeutics worth $274K as of Q2 2026.
  • Federated Hermes bought 10,000 Kyverna Therapeutics shares in Q2 2026, an estimated $88.8K.
  • Kyverna Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1469 holding.
  • Federated Hermes first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.